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1. Introduction 
The Ehlers-Danlos syndrome (EDS) is a heterogeneous group of heritable connective tissue 
disorders affecting as many as 1 in 5000 individuals, characterized by joint and skin laxity, 
and tissue fragility [1]. The fundamental mechanisms of EDS are known to consist of 
dominant-negative effects or haploinsufficiency of mutant procollagen α-chains and 
deficiency of collagen-processing-enzymes [2]. In a revised nosology established in the 
nomenclature conference held in June 1997 at Villefranche-sur-Mer, France, Beighton et al. 
[3] classified EDS into six major types (Table 1): classical type (OMIM#130000), 
hypermobility type (OMIM#130020), vascular type (OMIM#130050), kyphoscoliosis type 
(OMIM#225400), arthrochalasia type (OMIM#130060), and dermatosparaxis type 
(OMIM#225410). Additional minor variants of EDS have been identified with molecular and 
biochemical abnormalities: dermatan 4-O-sulfotransferase-1 (D4ST1)-deficient 
type/musculocontractural type (OMIM#601776), Brittle cornea syndrome (OMIM#229200), 
EDS-like syndrome due to tenascin-XB deficiency (OMIM#606408), EDS with progressive 
kyphoscoliosis, myopathy, and hearing loss (OMIM#614557); the spondylocheiro dysplastic 
form (OMIM#612350), cardiac valvular form (OMIM#225320), and progeroid form 
(OMIM#130070) [4] (Table 1). This chapter focuses on a recent breakthrough in EDS: 
discovery and delineation of D4ST1-deficient EDS (DD-EDS). 
2. History of D4ST1-deficient EDS 
DD-EDS, caused by loss-of-function mutations in the carbohydrate sulfotransferase 14 
(CHST14) gene coding D4ST1, has been identified independently as a rare type of 
arthrogryposis syndrome, “adducted thumb–clubfoot syndrome (ATCS)” [5]; as a specific 
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form of EDS, “EDS, Kosho Type” (EDSKT) [6]; and as a subset of kyphoscoliosis type EDS 
without evidence of lysyl hydroxylase deficiency, “Musculocontractural EDS” (MCEDS) [7]. 
 
§, a fraction number represents the prevalence such as “one affected person in 20,000 individuals” for “1/20,000” and 
an integral number represents the sum of previously reported patients; AD, autosomal dominant; AR, autosomal 
recessive; COL5A1 or COL5A2, α1(V) or α2(V) procollagen; TNXB, tenascin-X; #, in a small subset of cases; COL3A1, 
α1(III) procollagen; PLOD; lysyl hydroxylase; COL1A1 or COL1A2, α1(I) or α2(I) procollagen; *, splice-site mutations of 
the genes; ADAMTS2; procollagen I N-proteinase; CHST14, carbohydrate sulfotransferase 14; ZNF469, zinc finger 
protein 469; FKBP14, FK506-binding protein 14; SLC39A13, a membrane-bound zinc transporter; B4GALT7; 
xylosylprotein 4-beta-galactosyltransferase 
Table 1. Classification of Ehlers-Danlos Syndromes 
2.1. Adducted thumb–Clubfoot syndrome 
The original report of ATCS was written by Dündar et al. [8] from Erciyes University, 
Turkey, presenting two cousins, a boy aged 3.5 years and a girl aged 1.5 years, from a 
consanguineous Turkish family. In common, they had moderate to severe psychomotor 
developmental delay, ocular anterior chamber abnormality, facial characteristics, 
generalized joint laxity, arachnodactyly, camptodactyly, and distal arthrogryposis with 
adducted thumbs and clubfeet. They reported another patient with ATCS, a boy aged 3 
months, from a consanguineous Turkish family including three affected siblings who died 
of unknown etiology between the ages of 1 and 4 months [9]. The patient also had bilateral 
nephrolithiasis, a unilateral inguinal hernia, and bilateral cryptorchidism. The authors 
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suggested that two brothers, aged 22 months and 7 months, from a Japanese 
consanguineous family reported by Sonoda and Kouno [10] would also fit the diagnosis of 
ATCS. The brothers had multiple distal arthrogryposis, characteristic facial features, cleft 
palates, short stature, hydronephrosis, cryptorchidism, and normal intelligence. Dündar et 
al. [9] also showed follow-up observations of the original patients: the intelligence quotient 
(IQ) was roughly 90 in one subject at age 7 years and 2 months and the other died of 
unknown cause at 5 years of age. Janecke et al. [11] from Innsbruck Medical University, 
Austria, reported two brothers with ATCS from a consanguineous Austrian family, one of 
whom died shortly after birth because of respiratory failure. The authors concluded that all 
these patients represented a new type of arthrogryposis with central nervous system 
involvement, congenital heart defects, urogenital defects, myopathy, connective tissue 
involvement (generalized joint laxity), and normal or subnormal mental development. In 
2009, Dündar et al. reported that CHST14 was the causal gene for ATCS through 
homozygosity mapping using samples from four previously published consanguineous 
families. The authors mentioned some follow-up clinical findings including generalized 
joint laxity, delayed wound healing, ecchymoses, hematomas, and osteopenia/osteoporosis; 
and categorized ATCS as a generalized connective tissue disorder [5]. 
2.2. EDS, Kosho type 
We encountered the first patient with a specific type of EDS in 2000 and the second with 
parental consanguinity in 2003. They were Japanese girls with strikingly similar symptoms: 
characteristic craniofacial features; skeletal features including multiple congenital 
contractures, malfanoid habitus, pectus excavatum, generalized joint laxity, recurrent 
dislocations, and progressive talipes and spinal deformity; skin hyperextensibility, 
bruisability, and fragility with atrophic scars; recurrent hematomas; and hypotonia with 
mild motor developmental delay [12]. These symptoms overlapped those in the 
kyphoscoliosis type EDS (previously known as EDS type VI), which is typically associated 
with deficiency of lysyl hydroxylase (EDS type VIA) [13]. A rare condition with the clinical 
phenotype of the kyphoscoliosis type EDS but with normal lysyl hydroxylase activity were 
reported and named as EDS type VIB [13]. Therefore, we tentatively proposed that the two 
patients represented a clinically recognizable subgroup of EDS type VIB [12]. Through their 
long-term clinical evaluation as well as four additional unrelated Japanese patients 
including one with parental consanguinity and another reported by Yasui et al. [14], we 
concluded that they—four female patients and two male patients aged 4–32 years, 
represented a new clinically recognized type of EDS with distinct craniofacial 
characteristics, multiple congenital contractures, progressive joint and skin laxity, and 
multisystem fragility-related manifestations [15]. The disorder has been registered as  
EDS Kosho Type (EDSKT) in the London Dysmorphology Database 
(http://www.lmdatabases.com/index.html) and in POSSUM (http://www.possum.net.au/). 
In 2009, we identified CHST14 as causal for the disorder through homozygosity mapping 
using samples from two consanguineous families and all the other patients were also found 
to have compound heterozygous CHST14 mutations [6]. 
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2.3. Musculocontractural EDS 
Malfait et al. [7] from Ghent University, Belgium have found mutations in CHST14 through 
homozygosity mapping of two Turkish sisters and an Indian girl both presenting clinically 
with EDS VIB and with parental consanguinity. They had distinct craniofacial features, joint 
contractures, and wrinkled palms in addition to common features of kyphoscoliosis type 
EDS including kyphoscoliosis, muscular hypotonia, hyperextensible, thin, and bruisable 
skin, atrophic scarring, joint hypermobility, and variable ocular involvement. Malfait et al. 
[7] concluded that their series and ATCS, as well as EDSKT, formed a phenotypic 
continuum based on their clinical observations and identification of an identical mutation 
in both conditions; and proposed to coin the disorder as “musculocontractural EDS” 
(MCEDS). 
3. Pathophysiology of D4ST1-deficient EDS 
3.1. Glycobiological abnormalities in D4ST1-deficient EDS 
D4ST1 is a regulatory enzyme in the glycosaminoglycan (GAG) biosynthesis that transfers 
active sulfate to position 4 of the N-acetyl-D-galactosamine residues of dermatan sulfate 
(DS) (Fig. 1) [16, 17]. DS, together with chondroitin sulfate (CS) and heparan sulfate, 
constitutes GAG chains of proteoglycans and is implicated in cardiovascular disease, 
tumorigenesis, infection, wound repair, and fibrosis via DS-containing proteoglycans such 
as decorin and biglycan [18]. 
Sulfotransferase activity toward dermatan in the skin fibroblasts derived from the patients 
was significantly decreased to 6.7% (patient 1 with a compound heterozygous mutation: 
P281L/Y293C) and 14.5% (patient 3 with a homozygous mutation: P281L) of each age- and 
sex-matched control) (Fig. 2A). Disaccharide composition analysis of CS/DS chains isolated 
from the skin fibroblasts showed a negligible amount of DS and a slight excess of CS (Fig. 
2B). Subsequently, we focused on a major DS proteoglycan in the skin, decorin, consisting of 
core protein and one GAG chain and playing an important role in assembly of collagen 
fibrils (Nomura, 2006). No DS disaccharides were detected in the GAG chains of decorin 
from the patients, whereas the GAG chains of decorin from the controls were mainly 
composed of DS disaccharides (approximately 95%) (Fig. 2C) [6].  
3.2. Pathological abnormalities in D4ST1-deficient EDS 
Hematoxylin and eosin (H&E)-stained light microscopy on patients’ skin specimens showed 
that fine collagen fibers were present predominantly in the reticular to papillary dermis with 
marked reduction of normally thick collagen bundles (Fig. 3a, b). Electron microscopy 
showed that collagen fibrils were dispersed in the reticular dermis, compared with the 
regularly and tightly assembled ones observed in the control; whereas each collagen fibril 
was smooth and round, not varying in size and shape, similar to each fibril of the control 
(Fig. 3c, d) [6]. 
 





Table 2. Reported patients with D4ST1-deficient EDS 










Biosynthesis of chondroitin sulfate (CS) and dermatan sulfate (DS) starts with binding a tetrasaccharide linker region, 
glucuronic acid1-3galactose-3galactose1-4xylose1-O- (GlcA-Gal-Gal-Xyl-), onto serine (Ser) residues of specific 
core proteins of proteoglycans, by -xylosyltransferase (XylT), 1,4-galactosyltransferase-I (GalT-I), 1,3-
galactosyltransferase-II (GalT-II), and 1,3-glucuronosyltransferase-I (GlcAT-I), respectively. Subsequently, a 
disaccharide chain of chondroitin (C[N-acetyl-D-galactosamine(GalNAc)-GlcA]n is synthesized by N-acetyl-D-
galactosaminyltransferase-I (GalNAcT-I), N-acetyl-D-galactosaminyltransferase-II (GalNAcT-II), and CS-
glucuronyltransferase-II (CS-GlcAT-II) encoded by chondroitin synthase-1, 2, 3 (ChSy-1, 2, 3); and chondroitin 
polymerizing factor (ChPF). CS chains are matured through sulfation by chondroitin 4-O-sulfotransferase-1 (C4ST-1), 
chondroitin 6-O-sulfotransferase-1 (C6ST-1), and uronyl 2-O- sulfotransferase (UST). A disaccharide chain of dermatan 
(D) is synthesized through epimerization of a carboxyl group at C5 from GlcA to L-iduronic acid (IdoA) by dermatan 
sulfate epimease (DSE). DS chains are matured through sulfation by dermatan 4-O-sulfotransferase-1 (D4ST-1), 
dermatan 6-O-sulfotransferase-1 (D6ST-1), and UST. D4ST-1 deficiency, resulting in impaired 4-O-sulfation lock, 
probably allows back epimerization from IdoA to GlcA and finally leads to loss of DS and excess of CS. 
Figure 1.  Biosynthesis of dermatan sulfate and chondroitin sulfate. 
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A. Sulfotransferase activity of skin fibroblasts: A patient (a compound heterozygous mutation, P281L/Y293C; patient 
1), her heterozygous mother, and her age-matched control (control 1); another patient (a homozygous mutation, P281L; 
patient 3) and his age-matched control (control 2). B. The total amounts of CS and DS derived from skin fibroblasts. 
The total disaccharide contents of CS and DS are shown in a black box and a white box, respectively. C. Proportion of 
the disaccharide units in the CS/DS hybrid chains in decorin secreted by the fibroblasts. A white box and a light gray 
box indicate GlcUA-GalNAc (4S) and GlcUA-GalNAc (6S), respectively, both composing CS. A dark gray box and a 
black box indicate IdoUA-GalNAc(4S) and IdoUA-GalNAc (6S), respectively, both composing DS. 
Figure 2. Glycobiological studies [6]. 
 
H&E-stained light microscopy (LM) on skin specimens of a patient (a compound heterozygous mutation, 
P281L/C289S; patient 5) (a) and an age- and sex-matched control (b). Scale bars indicate 500 μm. Electron microscopy 
(EM) of the patient (c) and the control (d). Scale bars indicate 1 μm. 
Figure 3. Pathological studies [6]. 
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In view of these glycobiological and pathological findings, skin fragility in this disorder is 
suggested to be caused by impaired assembly of collagen fibrils resulting from loss of DS in 
the GAG chain of decorin [6]. Decorin DS regulates the interfibrillar distance in collagen 
fibrils and permits the extracellular matrix to resist physical stress, possibly through 
electrostatic interaction between decorin DS chains and adjacent collagen fibrils (Fig. 4A) 
[19]. Collagen fibrils are dispersed in patients’ skin tissues where the decorin GAG chains 
are exclusively composed of CS (Fig. 4B), whereas collagen fibrils in controls’ skin 
specimens are tightly assembled through the GAG chains of decorin exclusively composed 
of DS (Fig. 4A). 
 
 
Possible relationship between collagen fibrils and decorin in skin specimens of normal control subjects (A) and of 
patients (B). 
Figure 4. Schema of binding model of decorin to collagen fibrils [20]. 
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4. Delineation of D4ST1-deficient EDS 
Independently identified three conditions, ATCS, EDSKT, and MCEDS caused by loss-of-
function mutations in CHST14, were supposed to be a single clinically recognizable type 
of connective tissue disorder [7, 21]. Shimizu et al. [22] presented detailed clinical 
information of two additional unrelated patients and a comprehensive review of all 
reported 20 patients, which could definitely unite the three conditions named as “D4ST1-
deficient EDS (DD-EDS)”. Kosho et al. [23] concluded that categorization of the disorder 
into a form of “EDS” was appropriate clinically because the disorder satisfied all the 
hallmarks of EDS including skin hyperextensibility, joint hypermobility, and tissue 
fragility affecting the skin, ligaments, joints, blood vessels, and internal organs [1] and 
etiologically because multisystem fragility in the disorder was illustrated to be caused by 
impaired assembly of collagen fibrils resulting from loss of DS in the decorin GAG chains 
[6].  
To date, 26 patients have been reported to have homozygous or compound heterozygous 
CHST14 mutations (Table 2) [24, 25, 26]. Clinical characteristics are summarized in Table 3, 
consisting of progressive multisystem fragility-related manifestations and various 
malformations [23].  
Characteristic craniofacial features including large fontanelle, hypertelorism, short and 
downslanting palpebral fissures, blue sclerae, short nose with hypoplastic columella, low-
set and rotated ears, high palate, long philtrum, thin upper lip vermilion, small mouth, and 
micro-retrognathia are noted at birth to early childhood (Fig. 5A, B). Slender and 
asymmetrical facial shapes with protruding jaws are noted from school age (Fig. 5C) [12. 15, 
22]. 
Congenital multiple contractures, most specifically adduction-flexion contractures of 
thumbs and talipes equinovarus, were cardinal features (Fig. 5D, G, J, K, M). In childhood, 
peculiar fingers described as “tapering”, “slender”, and “cylindrical” are also common 
features (Fig. 5E, F, H, I). Talipes deformities (planus, valgus) (Fig. 5L, N) and spinal 
deformities (scoliosis, kyphoscoliosis) with tall vertebral bodies and decreased physiological 
curvature (Fig. 5O, P, Q, R, S, T) occur and progress. Malfanoid habitus, recurrent joint 
dislocations, and pectus deformities (flat and thin, excavatum, carinatum) are also evident 
[12. 15, 22].  
Cutaneous features include hyperextensibility (Fig. 5U, V) to redundancy (Fig. 5W), 
bruisability, fragility leading to atrophic scars, acrogeria-like fine palmar creases or wrinkles 
(Fig. 5F, I), hyperalgesia to pressure, and recurrent subcutaneous infections with fistula 
formation (Kosho et al., 2005; Kosho et al., 2010; Shimizu et al., 2011). 
Recurrent large subcutaneous hematomas are the most serious complication , which 
sometimes progress acutely and massively to be treated intensively (admission, blood 
transfusion, surgical drainage) and are supposed to be caused by rupture of subcutaneous 
arteries or veins (Fig. 5X) [12. 15, 22].  





Table 3. Clinical manifestations in DD-EDS [23] 
 




Figure 5. Clinical photographs of patients with DD-EDS [12, 15]. Patient 12 at birth (D), at age 23 days 
(A), 3 years (B), 6 years (X), and 16 years (C, E, F, O, P). Patient 13 at age 2 months (J, K), 3 months (G), 
14 months (U), 5 years (H), and 28 years (I, L, Q, R). Patient 14 in the neonatal period (M) and at age 28 
years (N, W). Patient 16 at age 19 years (S, T, V). Patient number is according to Table 2. 
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5. Conclusion 
DD-EDS is a newly recognized and delineated form of EDS, characterized by progressive 
multisystem fragility-related manifestations (skin hyperextensibilty and fragility, 
progressive spinal and foot deformities, large subcutaneous hematoma) and various 
malformations (facial features, congenital eye/heart/gastrointestinal defects, congenital 
multiple contractures). The cause of multisystem connective tissue fragility is supposed to 
be impaired assembly of collagen fibrils resulting from loss of DS in the decorin GAG 
chains. It is the first human disorder affecting biosynthesis of DS, which emphasize a role 
for DS in human development and extracellular matrix maintenance [27].  
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